



Zanubrutinib (Brukinsa®) Medically Integrated Oncology Treatment Discussion Guide

This guide equips members of the care team with the knowledge and confidence to lead meaningful treatment conversations—ensuring every patient feels supported, empowered, and prepared for their journey with zanubrutinib.

TABLE OF CONTENTS

PHARMACIST QUESTIONS	1
Medication Adherence and Instruction	1
Monitoring and Side Effects	1
Special Considerations	2
Monitoring for Drug Interactions	2
NURSING QUESTIONS	3
Medication Interactions	3
Special Considerations	3
PHYSICIAN AND ADVANCED	
PRACTICE PROVIDER (APP) QUESTIONS	5 4
Medication Information	4
Prognostic Factors and Monitoring	4
PHARMACY TECHNICIAN QUESTIONS	5
Prescription Pickup	5
Refills and Medication Instructions	5
Patient Assistance and Co-Pay Support	5

PHARMACIST QUESTIONS



Medication Adherence and Instruction



Question(s)

- ☐ How did your doctor instruct you to take zanubrutinib?
- ☐ How do you typically remember to take zanubrutinib?
- How long did your doctor say you will be on zanubrutinib?

Actionable Recommendations

If the patient is unsure about how to take the zanubrutinib

- ▶ Reinforce instructions
- Provide reminder examples such as setting alarms on their phones, or suggest pill organizers.

If patient is unsure of duration of treatment

▶ Reinforce that zanubrutinib is often a long-term treatment and is taken until disease progression or unacceptable toxicity.



Monitoring and Side Effects



Question(s)

- ☐ Has your doctor talked to you about possible side effects? If so, which ones? (fatigue, diarrhea, bruising, rash, or serious risks like excessive bleeding, increased risk of infections or heart rhythm changes)?
- Do you know how to manage symptoms like diarrhea at home and when to contact the clinic if they get worse?
- ☐ How will you monitor for signs and symptoms of infection? Bleeding?
- Which lab tests or monitoring did your doctor discuss that you will need while on zanubrutinib and how often?*

Actionable Recommendations

If the patient experiences heart palpitations, dizziness, or shortness of breath

▶ Educate them about the risk of atrial fibrillation (AFib) with zanubrutinib and encourage them to contact their provider immediately if they experience these symptoms. This helps detect early heart-related issues before they become serious.

If the patient is unsure about managing diarrhea at home

Educate them on staying hydrated with electrolyterich fluids and using over-the-counter antidiarrheal medications if appropriate.

If the patient is unaware of the need for lab monitoring

▶ Educate them on the importance of routine CBCs and liver function tests to detect issues like neutropenia, thrombocytopenia, or liver enzyme elevations.

*The answer to this question will be different for each patient, but the question is recommended that it is asked.





Special Considerations



Question(s)

- ☐ Did your doctor discuss the importance of the use of sun protection daily and monitoring for development of other cancers?
- ☐ How are you currently protecting your skin from the sun?
- ☐ Have you noticed any changes in your skin since starting zanubrutinib?

Actionable Recommendations

If patient is not using daily sun protection

- Advise on the importance of wearing sunscreen and the use of other sun protective measures
- Zanubrutinib can increase sensitivity to sunlight and raise the risk of certain skin cancers, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).



Monitoring for Drug Interactions



Question(s)

☐ How often do you consume grapefruit or grapefruit juice in your diet?

Actionable Recommendations

If the patient is unaware of dietary restrictions

- Reinforce that they should avoid grapefruit and grapefruit juice, as it can increase zanubrutinib levels and the risk of side effects.
- Modify zanubrutinib dose accordingly if co-administered with: (1) Strong CYP3A inhibitor: 80 mg once daily; (2) Moderate CYP3A inhibitor: 80 mg twice daily; (3) Moderate or Strong CYP3A inducer: Avoid concomitant use.



NURSING QUESTIONS



Medication Interactions



Question(s)

Since starting zanubrutinib:

- ☐ Have you seen any unexpected bruising or bleeding, like nosebleeds or blood in your urine or stool?
- ☐ Have you had any fevers, chills, persistent cough, or other signs of infection?
- Have you experienced dizziness, increased heart beats/heart palpitations, chest pain, or any episodes of fainting?
- ☐ Have you had any skin changes, such as new or changing moles, rashes, or sores that don't heal?
- ☐ Have you experienced abdominal pain, dark urine, yellowing of the skin or eyes, or any signs of liver issues?

Actionable Recommendations

If the patient reports unexplained bruising or bleeding

Reinforce that zanubrutinib increases the risk of bleeding, and they should avoid NSAIDs and other blood-thinning medications unless prescribed.

If the patient reports fevers, chills, persistent cough, or other signs of infection

Educate on the increased risk of infections with zanubrutinib. Encourage immediate reporting of fever ≥100.4°F (38°C) or signs of infection for prompt management.

If the patient experiences abdominal pain, dark urine, jaundice, or other signs of liver issues

Assess for hepatotoxicity. Consider liver function testing and refer to the provider for further evaluation.



Special Considerations



Question(s)

- Did your doctor discuss the importance of the use of sun protection daily and monitoring for development of other cancers?
- ☐ What do you currently do to protect your skin from the sun?
- ☐ Have you noticed any changes in your skin since starting zanubrutinib?

Actionable Recommendations

If patient is not using daily sun protection

- Advise them to generously apply a broad-spectrum UVA/ UVB water-resistant sunscreen; re-apply about every 2 hours and after swimming or sweating.
- Advise them to wear protective clothing and seek shade when appropriate.
- Zanubrutinib can increase sensitivity to sunlight and raise the risk of certain skin cancers, including BCC and SCC.



PHYSICIAN AND APP QUESTIONS



Medication Information



Question(s)

- Do you have any questions about how we will know if zanubrutinib is working for you?
- Would you like more information on how we will track your progress with this treatment?

Actionable Recommendations

Explain the goals of treatment to the patient

- Potential goals of therapy include reducing symptoms or keeping the disease stable.
- Explain how blood counts/labs will be monitored to see if cancer is responding to treatment



Prognostic Factors and Monitoring



Question(s)

- ☐ Did your doctor order genetic testing to help choose the best treatment plan for you?
- □ Do you have a history of atrial fibrillation, arrhythmias, or other heart problems?
- Do you know how to identify new symptoms that you should share with care team? (e.g., lightheaded, dizziness, chest discomfort, black or tarry stools, and/or bruising)
- ☐ Have you undergone an electrocardiogram (EKG) or other heart test to monitor heart rhythm changes?
- ☐ If so, did your doctor discuss any findings with you?

Actionable Recommendations

If the patient has a history of AFib or other heart problems

- Assess the severity and frequency of AFib episodes.
- Monitor closely for worsening cardiac symptoms.
- Evaluate the need for anticoagulation therapy, balancing stroke risk with the increased bleeding risk from zanubrutinib.





PHARMACY TECHNICIAN QUESTIONS



Prescription Pickup



Question(s)

- How have you been advised to store zanubrutinib at home? Do you know that it should be kept at room temperature, away from heat, moisture, and direct sunlight?
- Do you have any concerns about when and how you'll receive your zanubrutinib?
- Would you like a reminder when it's time to refill your zanubrutinib?

Actionable Recommendations

If the patient has concerns about how and when they will receive their zanubrutinib

- Confirm their preferred pharmacy and delivery method (mail order, specialty pharmacy, or in-person pick-up).
- Assist in tracking shipments and coordinating refills to prevent delays.



Refills and Medication Instructions



Question(s)

- ☐ How many days of zanubrutinib do you have left?
- ☐ Do you need assistance ensuring you don't run out?
- Do you have enough zanubrutinib to last until your next refill?

Actionable Recommendations

If there are potential delays due to insurance/supply issues

Proactively coordinate with all stakeholders to explore expedited shipping, emergency supplies, or alternative access options.



Patient Assistance and Co-Pay Support



Question(s)

- ☐ We are working on your insurance approval for zanubrutinib. Have you been informed about potential copay costs and assistance options?
- Would you like help applying for financial assistance?

Actionable Recommendations

If the patient is unaware of copay costs and assistance

- Inform them about financial assistance and direct them to myBeOneSupport™ (1-833-234-4363)
- ▶ For additional information and support: https://www.mybeonesupport.com/brukinsa/patient/



www.ncoda.org